1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
3.37
Current Ratio near Biotechnology median of 3.60. Charlie Munger would see it as typical for the industry.
3.37
Quick Ratio near Biotechnology median of 3.50. Charlie Munger could see typical near-cash readiness for the sector.
3.18
Cash Ratio above 1.5x Biotechnology median of 1.82. Joel Greenblatt might see a strategic advantage in crisis periods.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.